曲伏前列素眼内植入物治疗开角型青光眼或高眼压症的安全性和有效性的3期随机临床试验
这项多中心、随机、双盲、假手术对照的非劣效性3期试验评估了两种曲伏前列素眼内植入物(快速释放型和缓慢释放型)在开角型青光眼或高眼压症患者中的安全性和降眼压疗效,并与每日两次0.5%噻吗洛尔滴眼液进行比较。结果显示两种植入物在3个月主要疗效评估期内均展现出强劲的降眼压效果,其降眼压疗效在统计学和临床上均非劣效于噻吗洛尔组,且安全性良好。
要点
- 快速释放型植入物组平均眼压降幅为6.6至8.4 mmHg,缓慢释放型组为6.6至8.5 mmHg,噻吗洛尔组为6.5至7.7 mmHg。
- 主要疗效终点达成,植入物组与噻吗洛尔组差异的95%置信区间上限在所有6个时间点均小于1 mmHg。
- 研究眼不良事件发生率分别为快速释放型21.5%、缓慢释放型27.2%、噻吗洛尔10.8%,大多为轻中度。
核心结论
- 曲伏前列素眼内植入物在单次给药后3个月主要疗效评估期内展现出强劲的降眼压效果。
- 两种植入物组的降眼压疗效在统计学和临床上均非劣效于噻吗洛尔组,且安全性良好。
研究设计与样本
- 多中心、随机、双盲、假手术对照的非劣效性3期试验(GC-010试验)。
- 研究对象为未用药基线平均日间眼压(8 am、10 am和4 pm时间点平均值)≥21 mmHg且基线各时间点眼压≤36 mmHg的开角型青光眼或高眼压症患者。
- 研究眼随机分配至曲伏前列素眼内植入物快速释放型组(n=200)、缓慢释放型组(n=197)或0.5%噻吗洛尔滴眼液每日两次组(n=193)。
主要发现
- 快速释放型植入物组平均眼压较基线降幅为6.6至8.4 mmHg,缓慢释放型组为6.6至8.5 mmHg,噻吗洛尔组为6.5至7.7 mmHg。
- 主要疗效终点达成,植入物组与噻吗洛尔组差异的95%置信区间上限在所有6个时间点均<1 mmHg。
- 研究眼不良事件发生率分别为快速释放型组21.5%、缓慢释放型组27.2%、噻吗洛尔组10.8%,大多为轻中度。
- 常见不良事件包括虹膜炎(快速释放型0.5%;缓慢释放型5.1%)、眼充血(快速释放型3.0%;缓慢释放型2.6%)、视力下降(快速释放型1.0%;缓慢释放型4.1%;噻吗洛尔0.5%)和眼压升高(快速释放型3.5%;缓慢释放型2.6%;噻吗洛尔2.1%)。
- 发生1例严重研究眼不良事件(眼内炎)。
关键数值与推荐
- 主要结局为研究眼在10天、6周和3个月时8 am和10 am的眼压较基线平均变化。
- 快速释放型植入物组平均眼压降幅为6.6至8.4 mmHg,缓慢释放型组为6.6至8.5 mmHg,噻吗洛尔组为6.5至7.7 mmHg。
- 植入物组与噻吗洛尔组差异的95%置信区间上限在所有6个时间点均<1 mmHg,达到非劣效性。
- 研究眼不良事件发生率:快速释放型组21.5%,缓慢释放型组27.2%,噻吗洛尔组10.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and intraocular pressure (IOP)-lowering efficacy of 2 models of the travoprost intraocular implant (fast-eluting [FE] and slow-eluting [SE] types) from 1 of 2 phase 3 trials (the GC-010 trial). DESIGN: Multicenter, randomized, double-masked, sham-controlled, noninferiority trial. PARTICIPANTS: Patients with open-angle glaucoma or ocular hypertension having an unmedicated baseline mean diurnal IOP (average of 8 am, 10 am, and 4 pm time points) of ≥ 21 mmHg, and IOP of ≤ 36 mmHg at each of the 8 am, 10 am, and 4 pm timepoints at baseline. METHODS: Study eyes were randomized to the travoprost intraocular implant (FE implant [n = 200] or SE implant [n = 197] model) or to timolol ophthalmic solution 0.5% twice daily (n = 193). MAIN OUTCOME MEASURES: The primary outcome was mean change from baseline IOP in the study eye at 8 am and 10 am, at each of day 10, week 6, and month 3. Safety outcomes included adverse events (AEs) and ophthalmic assessments. RESULTS: Mean IOP reduction from baseline over the 6 time points ranged from 6.6 to 8.4 mmHg for the FE implant group, from 6.6 to 8.5 mmHg for the SE implant group, and from 6.5 to 7.7 mmHg for the timolol group. The primary efficacy end point was met; the upper limit of the 95% confidence interval of the difference between the implant groups and the timolol group was < 1 mmHg at all 6 time points. Study eye AEs, most of mild or moderate severity, were reported in 21.5%, 27.2%, and 10.8% of patients in the FE implant, SE implant, and timolol groups, respectively. The most common AEs included iritis (FE implant, 0.5%; SE implant, 5.1%), ocular hyperemia (FE implant, 3.0%; SE implant, 2.6%), reduced visual acuity (FE implant, 1.0%; SE implant, 4.1%; timolol, 0.5%), and IOP increased (FE implant, 3.5%; SE implant, 2.6%; timolol, 2.1%). One serious study eye AE occurred (endophthalmitis). CONCLUSIONS: The travoprost intraocular implant demonstrated robust IOP reduction over the 3-month primary efficacy evaluation period after a single administration. The IOP-lowering efficacy in both implant groups was statistically and clinically noninferior to that in the timolol group, with a favorable safety profile. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Sarkisian SR, Ang RE, Lee AM, et al. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology. 2024. PMID: 38423216. doi:10.1016/j.ophtha.2024.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。